Most Read Articles
5 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 4 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
4 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh
07 Dec 2018

Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

“Nearly one in five patients with cancer will develop a clot in the veins … Clotting events can be deadly, with pulmonary embolism being the second most common cause of death in [patients with] cancer,” said Dr Robert McBane from the Mayo Clinic in Rochester, Minnesota, US.

The current guideline-recommended treatment for cancer-associated VTE is LMWH, but LMWH injections are expensive and can cause bruising and pain at the injection site, said McBane. “Patients [with cancer] may experience low platelet counts and be at risk for a clotting disorder called heparin-induced thrombocytopenia.” Also, kidney injury induced by cancer therapy can further limit the use of LMWH.  

Compared with the LMWH dalteparin, apixaban significantly reduced the risk of recurrent VTE in cancer patients by 90.1 percent (hazard ratio [HR], 0.099; p=0.03), with VTE recurrence observed in 0.7 percent of apixaban-treated patients vs 6.3 percent in the dalteparin group. [ASH 2018, abstract 421]

Major bleeding rates were comparable between the apixaban and dalteparin groups (0 percent vs 1.4 percent; p=0.14), indicating that apixaban is safe. Major plus clinically relevant nonmajor bleeds also occurred at similar rates in both groups (6.2 percent vs 6.3 percent; p=0.88).

There were no significant differences in mortality rates at 6 months between the two groups (HR, 1.40; p=0.31).

Based on monthly quality-of-life surveys, patients showed that they preferred apixaban over dalteparin when considering burden of delivery, concerns for excess bruising, irritation, stress, and overall satisfaction with anticoagulants (p<0.05).

“Apixaban was well tolerated with superior patient satisfaction and significantly fewer study drug discontinuations compared with dalteparin,” said McBane, who noted that more patients in the dalteparin group discontinued treatment compared with the apixaban group (15 percent vs 4 percent; p=0.0012). “These data support the use of apixaban for the acute treatment of cancer-associated VTE.”

The multicentre, open-label trial randomized 287 patients (mean age, 64 years) with cancer in a 1:1 ratio to receive apixaban twice daily (10 mg for 7 days followed by 5 mg dose) or subcutaneous dalteparin (200 IU/kg for 1 month and subsequently 150 IU/kg once daily) for 6 months. About two-third of the patients (65.5 percent) had metastatic disease, with lung, pancreas, colorectal, and breast cancers being the four most prevalent cancer types.

“As a class, [direct oral anticoagulants] have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels,” said McBane.

“We are hopeful that this medication will also improve medication compliance in patients [with cancer] requiring blood thinner therapy,” he added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 4 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
4 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.